Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

21st Century Cures Act

FDA Commissioner Gottlieb Ends Trump’s Hiring Freeze at Agency

Washington, DC, June 7, 2017 — Food and Drug Administration (FDA) Commissioner Scott Gottlieb, M.D., has pulled the plug on the hiring freeze President Donald Trump imposed on the agency.

The moves will allow the FDA to fill vacancies to shape an agency capable of enacting his plans for how safety and efficacy information are gathered during development. Continue reading

Rebuffing Trump’s Call for Cuts, Congress Boosts NIH Funding by $2 Billion

Washington, DC, May 1, 2017 — Lev Facher reports in STAT that the National Institutes of Health will get a $2 billion funding boost over the next five months, under a bipartisan spending deal reached late Sunday night in Congress.

The agreement marks a sharp rejection of President Trump’s proposal to cut $1.2 billion from the medical research agency in the current fiscal year.

The deal does not address funding for 2018, when Trump has called for a slashing the NIH’s budget by about a fifth, or $5.8 billion. Continue reading

Trump’s Budget Proposes 18 Percent Cut for NIH; $26 Billion Lowest in 15 Years

President Donald Trump

Washington, DC, March 16, 2017 — Thomas M. Burton reports in The Wall Street Journal that funding for the National Institutes of Health (NIH), the nation’s premier medical research funding agency, would be cut by 18 percent, or $5.8 billion, from levels enacted for fiscal 2017, under the Trump administration budget.

The NIH’s budget would total just under $26 billion, the lowest level in 15 years.

The Trump administration’s plan appears to put it on a collision course with leaders of both parties in Congress. Continue reading

President Obama Signs 21st Century Cures Legislation; Aims to Accelerate Medical Innovation

President Barack Obama

President Barack Obama

Washington, DC, December 14, 2016 — President Obama signed legislation Tuesday that aims to increase funding for medical research, speed the development and approval of experimental treatments and overhaul federal policy on mental health care, Juliet Eilperin and Carolyn Y. Johnson report in The Washington Post.

“We are bringing to reality the possibility of new breakthroughs to some of the greatest health-care challenges of our time,” President Obama said.

“It is wonderful to see how well Democrats and Republicans in the closing day of this Congress came together around a common cause,” Obama said.  “And I think it indicates the power of this issue and how deeply it touches every family across America.” Continue reading

Congress Passes 21st Century Cures Act; President Obama Praises Bill to Accelerate Medical Innovation

21st-century-cures-blueWashington, DC, December 8, 2016 — Mike DeBonis reports in The Washington Post that Congress passed sweeping legislation yesterday that boosts funding for medical research, eases the development and approval of experimental treatments and reforms federal policy on mental health care.

The 94 to 5 Senate vote Wednesday followed a 392 to 26 House vote last week.

The bill, known as the 21st Century Cures Act, now heads to the desk of President Obama, who praised the bill Wednesday and said he would sign it. Continue reading

U.S. House Approves 21st Century Cures Bill, A Sweeping Health, Medical Innovation Measure

21st-century-cures-blueWashington, DC, December 1, 2016 — Jennifer Steinhauer and Sabrina Tavernise report in The New York Times that the U.S. House or Representatives yesterday overwhelmingly passed a far-reaching measure — the 21st Century Cures Act — to increase funding for research into cancer and other diseases, address weaknesses in the nation’s mental health systems and help combat the prescription drug addictions that have bedeviled nearly every state.

In a statement, House Energy and Commerce Committee Chairman Fred Upton (R-MI) and Rep. Diana DeGette (D-CO), co-authors of the bill, said, “21st Century Cures is the innovation game-changer that patients, their loved ones, and the nation’s researchers and scientists so desperately need.”

“The White House has expressed its enthusiastic endorsement of this critical legislation,” Upton and DeGette said.  “So it’s now on to the Senate, where we are just one final vote away from delivering #CuresNow.” Continue reading

Long-Stalled 21st Century Cures Act Sits on Senate’s Lame-Duck Calendar

Capitol Dome HEALTHCAREWashington, DC, November 24, 2016 — Steven Findlay reports in The Washington Post that Republicans in Congress are pushing to pass long-stalled legislation by December that gives the Food and Drug Administration (FDA) new powers to more rapidly approve drugs and medical devices.

Over five years, the complex legislation would include $550 million in additional funding for the agency, plus upward of $1 billion annually in added spending for the National Institutes of Health.

The bills have had bipartisan support in Congress during the past two years. Continue reading

Research Groups Push Back on Capitol Hill Talk of Delaying 21st Century Cures Acts

Capitol Dome flag faveWashington, DC, November 2, 2016 — Peter Sullivan reports in The Hill that research advocates are calling on Congress to pass a medical cures bill this year after a coalition of liberal groups asked to delay it.

Research America — which includes universities, drug companies and disease groups, and United for Medical Research, which includes universities and groups like the American Cancer Society — both sent letters to congressional leadership calling for action on the bill, known as 21st Century Cures. Continue reading

Opinion: For Medical Miracles, Empower Life Sciences Companies — Don’t Vilify Them

Medical Innovation 6Washington, DC, October 28, 2016Former United States Senator Tom Coburn, M.D., and Paul Howard, Ph.D., director of health policy, Manhattan Institute, and co-author of the new book, “Unlocking Precision Medicine,” write in The Hill:

“We can do virtually anything,” Vice President Joe Biden told the Cleveland crowd. “Your children are going to see more progress in the next 15 years than we’ve seen in the last 75 years.”

With these words, Biden opened the Cleveland Clinic’s medical innovation summit on Monday. The progress he spoke of is in the fight against cancer, where the next generation of American cures is set to radically shift the medical landscape. Continue reading

Minority Leader Pelosi Predicts 21st Century Cures Bill ‘Will Pass’ This Year

Capitol Dome HEALTHCAREWashington, DC, October 21, 2016 — Sarah Ferris reports in The Hill reported that House Minority Leader Nancy Pelosi (D-Calif.) is predicting that the latest version of the 21st Century Cures bill would have enough votes to pass this year.

Pelosi said during a press conference on Wednesday that she would “build consensus” on a new version of the medical cures bill, which is expected to come up in a lame-duck session of Congress.

The bill passed almost unanimously in the House last summer but has stalled in the Senate over concerns on how to pay for a half-decade’s worth of new research spending, totaling roughly $9 billion. Continue reading